Drugs / FRAME-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04998474 | Jan 2022 → Jan 2024 | non-small cell lung carcinoma | Frame Pharmaceuticals B.V. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRAME-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04998474 ↗ |
| Modality | Vaccine | “personalized peptide vaccine FRAME-001” NCT04998474 ↗ |
| Route | Subcutaneous | “up to four subcutaneous injections” NCT04998474 ↗ |